A new compound, discovered jointly by international pharmaceutical company Servier, headquartered in France, and Vernalis (R&D), a company based in the UK, has been shown by researchers at the Walter and Eliza Hall Institute and Servier to block a protein that is essential for the sustained growth of up to a quarter of all cancers.
The research presents a new way to efficiently kill these cancerous cells and holds promise for the treatment of blood cancers such as acute myeloid leukaemia,lymphoma and multiple myeloma, as well as solid cancers such as melanoma and cancers of the lung and breast. It is published online today in the journal Nature.
The Servier compound – S63845 – targets a protein of the BCL2 family, called MCL1, which is essential for the sustained survival of these cancer cells.
Institute scientist Associate Professor Guillaume Lessene, who led the Walter and Eliza Hall Institute’s research team in Melbourne, Australia, said the work provided the first clear preclinical evidence that inhibiting MCL1 was effective in targeting several cancer types.
“MCL1 is important for many cancers because it is a pro-survival protein that allows the cancerous cells to evade the process of programmed cell death that normally removes cancer cells from the body,” Associate Professor Lessene said. “Extensive studies performed in a variety of cancer models have shown that S63845 potently targets cancer cells dependent on MCL1 for their survival.”
The institute team of Associate Professor Lessene worked with haematologist Associate Professor Andrew Wei and Dr Donia Moujalled from The Alfred Hospital and Servier scientists, to demonstrate that not only was S63845 effective against several cancer types, but that it could also be delivered at doses that were well tolerated by normal cells.
Dr Olivier Geneste, Director of Oncology Research at Servier, said this preclinical research represented major findings regarding the druggability of MCL1, a valuable and highly challenging target. “S63845 was discovered through collaboration with the fragment and structure based discovery expertise at Vernalis,” he said. “As part of the ongoing Servier / Novartis collaboration on this target class, clinical development of a MCL1 inhibitor should be launched in the near future.”
Associate Professor Lessene said the research provided further evidence of the usefulness of a new class of anti-cancer drugs called BH3 mimetics. “BH3 mimetics inhibit a group of proteins known as the ‘pro-survival BCL-2 proteins’,” he said. “MCL1 is a member of this protein family, and inhibiting it activates the process of programmed cell death. Walter and Eliza Hall Institute researchers revealed the role of BCL-2 in cancer more than 28 years ago and the essential role of MCL1 for the survival of malignant cells four years ago.”
The Latest on: Cancer treatment
via Google News
The Latest on: Cancer treatment
- Radiation and surgery do not prolong survival in newly diagnosed metastatic breast canceron May 28, 2020 at 9:44 pm
Up to now, women who present with a new diagnosis of breast cancer that is already in an advanced stage (stage IV) face an unanswered question about whether surgery and radiation to the tumor in the ...
- Bacterial colonies of tumors could guide cancer careon May 28, 2020 at 7:19 pm
The human body is teeming with bacteria, and a new study finds the same is true of many cancers -- raising questions about what role microbes might play in the diseases.
- AstraZeneca's Top-Selling Drug Slows Early-Stage Lung Cancer-Trialon May 28, 2020 at 6:14 pm
The company will now push for earlier diagnosis of lung cancer, to have more patients benefit from a possible new treatment option, said Astra's head of oncology drug research and development Jose ...
- Cancer and COVID-19: What’s the Outlook?on May 28, 2020 at 2:30 pm
Cancer patients diagnosed with COVID-19 who are otherwise generally healthy can and do survive the coronavirus, but the news isn't as good for those who also had other medical issues.
- Cancer, coronavirus are a dangerous mix, new studies findon May 28, 2020 at 2:25 pm
New research shows how dangerous the coronavirus is for current and former cancer patients. Those who developed COVID-19 were much more likely to die within a month than people without cancer who got ...
- Study Opens Up Possibility for Use of Precision Medicine in Pediatric Canceron May 28, 2020 at 2:07 pm
Children who were treated with matched drugs judged to have the highest potential for effectiveness achieved a median progression-free survival of 204.5 days compared with 114 days for all the other ...
- HCQ Linked to Harm in Cancer Patientson May 28, 2020 at 2:07 pm
Treatment with the combination of hydroxychloroquine and azithromycin to treat COVID-19 in cancer patients was associated with a 2.89-fold greater risk of 30-day mortality than use of neither drug, ...
- The changing landscape of cancer in the USA — opportunities for advancing prevention and treatmenton May 28, 2020 at 8:33 am
Monitoring both cancer incidence and death rates is important for guiding health policy and the direction of future research. In this Perspective, the authors describe changes in cancer incidence and ...
- Rush Limbaugh gives candid update on his battle with advanced lung canceron May 28, 2020 at 8:16 am
Rush Limbaugh doesn't want to "divulge" too much about his advanced lung cancer diagnosis, but he did provide a candid update on Tuesday's show.
via Bing News